Intranasal dexmedetomidine (Group D)	Intranasal saline 0.9% (Group C)	Need of nalbuphine for pain and agitation episodes after surgery	13780	13951	Postoperative nalbuphine dose consumption as a rescue medication for agitation episodes and pain was significantly higher in Group C compared with Group D with a P = 0.001
Intranasal dexmedetomidine (Group D)	Intranasal saline 0.9% (Group C)	Emergence agitation 	1254	1381	There was a significant difference in the incidence of EA between Groups D and C (6.98% and 58%, respectively, with P = 0.001).
Intranasal dexmedetomidine (Group D)	Intranasal saline 0.9% (Group C)	Extubation times	13483	13635	There was no statistically significant difference between the two groups regarding extubation, emergence, and discharge times with a P > 0.05 [Table 4].
Intranasal dexmedetomidine (Group D)	Intranasal saline 0.9% (Group C)	Discharge times	13483	13624	There was no statistically significant difference between the two groups regarding extubation, emergence, and discharge times with a P > 0.05
Intranasal dexmedetomidine (Group D)	Intranasal saline 0.9% (Group C)	Median scores of FLACC pain	1382	1563	The median four-point agitation scales and the median scores of FLACC pain scales of Group D were significantly lower than those of Group C at the all six time points with P < 0.05.
Intranasal dexmedetomidine (Group D)	Intranasal saline 0.9% (Group C)	Discharge times	1564	1693	Extubation, emergence, and discharge times were comparable in both groups, and none of the subjects reported any adverse effects.
Intranasal dexmedetomidine (Group D)	Intranasal saline 0.9% (Group C)	Extubation times	13483	13624	There was no statistically significant difference between the two groups regarding extubation, emergence, and discharge times with a P > 0.05
Intranasal dexmedetomidine (Group D)	Intranasal saline 0.9% (Group C)	Median scores of FLACC pain	1425	1562	the median scores of FLACC pain scales of Group D were significantly lower than those of Group C at the all six time points with P < 0.05
